Genotyping Market By Product Type (Reagents and Kits, Instruments, Software & Services), By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Microarray Technology, Mass Spectrometry, CRISPR Technology), By Application (Disease Diagnostics, Agricultural Genotyping, Forensic Applications, Personalized Medicine, Pharmacogenomics), By End-User Industry (Pharmaceutical & Biotechnology Companies, Healthcare Providers, Research Institutes, Academic Institutions, Government Agencies), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Genotyping Market was valued at USD 11.7 billion in 2024-e and will surpass USD 32.8 billion by 2030; growing at a CAGR of 15.9% during 2025 - 2030.

The Genotyping Market is an essential part of the broader genomics industry, playing a crucial role in understanding genetic variations and enabling advancements in personalized medicine, disease diagnostics, and agricultural development. It encompasses various technologies and applications aimed at identifying genetic markers, mutations, and traits that influence disease predisposition, treatment responses, and overall health. The market has witnessed substantial growth driven by technological advancements in sequencing, improved accuracy in detection, and the increasing demand for personalized and precision medicine. As more industries, such as agriculture and healthcare, recognize the value of genotyping, the market is expected to continue expanding rapidly.

Reagents and Kits Segment is Largest Owing to Increased Demand in Diagnostic and Research Applications

Among the product types, reagents and kits are the largest segment in the genotyping market. These products are widely used in disease diagnostics, agricultural research, and various molecular biology applications, owing to their critical role in preparing DNA samples for analysis. Reagents and kits are essential for performing tasks such as PCR amplification, genotyping assays, and sequencing, making them indispensable for research laboratories, diagnostic centers, and pharmaceutical companies. The broad applicability of these reagents in diverse fields has driven high demand, particularly with the growing focus on personalized medicine and the need for precise genetic analysis in clinical settings.

As the demand for customized treatments and genetic testing grows, the market for reagents and kits continues to expand. The advancement of CRISPR and next-generation sequencing (NGS) technologies has further increased the demand for high-quality reagents and kits that can deliver reliable, reproducible results. With growing applications in cancer diagnostics, genetic screening, and agricultural genomics, this segment is expected to maintain its leading position in the market.

Next-Generation Sequencing (NGS) Technology is Fastest Growing Owing to Technological Advancements and Cost Reductions

Next-Generation Sequencing (NGS) technology is rapidly growing and is expected to dominate the genotyping market in the coming years. NGS allows for high-throughput and accurate sequencing of DNA and RNA, providing comprehensive genetic information more efficiently and at a lower cost compared to traditional sequencing methods. This technology has revolutionized genomics, enabling whole-genome sequencing, transcriptome analysis, and targeted gene sequencing in various research, clinical, and pharmaceutical applications. The dramatic reduction in sequencing costs and the increasing adoption of NGS for applications such as genetic disorder screening and precision medicine have contributed to its rapid growth.

The increasing demand for NGS technology in the healthcare and pharmaceutical industries is a key driver of this growth. NGS provides clinicians and researchers with the tools needed for early disease detection, personalized treatment planning, and targeted therapies. As advancements continue to improve NGS systems and bioinformatics tools, the accessibility and affordability of NGS are expected to increase, further driving its adoption and expansion in the genotyping market.

Disease Diagnostics Application is Largest Due to Growing Focus on Early Detection and Precision Medicine

The largest application of genotyping is in disease diagnostics. As the healthcare industry increasingly embraces precision medicine, genetic testing has become an essential tool in identifying predispositions to diseases, tailoring treatments to individuals, and monitoring treatment outcomes. Genotyping plays a pivotal role in diagnosing genetic disorders, identifying mutations linked to various cancers, cardiovascular diseases, and neurological conditions. The ability to analyze a patient’s genetic profile allows for more accurate disease diagnosis, enabling healthcare providers to offer targeted treatments that are more effective and have fewer side effects.

Genetic tests are now part of routine medical care in many developed countries, leading to a growing demand for diagnostic tools that provide genetic insights. The rise in chronic diseases and the increased emphasis on personalized healthcare are likely to further fuel the growth of genotyping in disease diagnostics. As a result, this segment continues to see significant investment from healthcare providers, pharmaceutical companies, and biotechnology firms focused on enhancing diagnostic accuracy and improving patient outcomes.

Pharmaceutical and Biotechnology Companies Industry is Largest End-User Due to Drug Development and Research Investments

Pharmaceutical and biotechnology companies represent the largest end-user industry in the genotyping market. These companies are heavily involved in drug discovery and development processes, utilizing genotyping technologies to understand genetic variations that may influence drug responses. Genotyping aids in identifying genetic markers associated with diseases and therapeutic outcomes, making it an essential tool for pharmaceutical research. Furthermore, the increasing integration of genetic testing into clinical trials and personalized medicine initiatives has further boosted demand within this sector.

The focus on pharmacogenomics, where the genetic makeup of individuals influences drug efficacy and safety, has intensified pharmaceutical companies’ reliance on genotyping. With the growing need for targeted therapies and the development of more effective drugs, pharmaceutical and biotechnology companies continue to drive innovation and investments in genotyping technologies. This trend is expected to sustain the dominance of the pharmaceutical and biotechnology industry in the genotyping market.

North America Region is Largest Due to Advanced Healthcare Infrastructure and Research Capabilities

North America is the largest region in the genotyping market, primarily driven by its well-established healthcare infrastructure, advanced research capabilities, and high healthcare spending. The region has witnessed significant adoption of genetic testing technologies in both clinical diagnostics and research applications, with a growing emphasis on precision medicine and personalized healthcare. Major pharmaceutical and biotechnology companies based in the U.S. and Canada are increasingly investing in genotyping technologies, further boosting demand in the region.

The presence of leading academic institutions and research institutes in North America also plays a key role in advancing the development and application of genotyping technologies. With ongoing government support for genomic research and the widespread adoption of NGS, the North American market is expected to maintain its leadership position in the global genotyping market.

Competitive Landscape and Leading Companies

The genotyping market is highly competitive, with several global companies leading the way in terms of innovation and market share. Key players in the market include Thermo Fisher Scientific, Illumina, Agilent Technologies, Roche, and Qiagen, which are at the forefront of providing advanced genotyping platforms, reagents, and kits. These companies have established strong partnerships with healthcare providers, research institutions, and pharmaceutical companies, facilitating the integration of genotyping technologies into various applications, including disease diagnostics and drug discovery.

As the market continues to grow, companies are focusing on expanding their product portfolios, enhancing the accuracy and efficiency of their technologies, and reducing costs to remain competitive. In addition, partnerships, mergers, and acquisitions are expected to play a significant role in shaping the future landscape of the genotyping market, with companies seeking to broaden their capabilities and reach new markets

Recent Developments:

• Illumina recently launched the NovaSeq 6000, a high-throughput genotyping platform designed to improve genomic research efficiency and accuracy.
• Thermo Fisher Scientific has partnered with pharmaceutical companies to advance genotyping technologies used in pharmacogenomic studies, improving drug development timelines.
• Agilent Technologies received regulatory approval for its latest genotyping platform, providing enhanced precision for clinical applications.
• Qiagen acquired a molecular diagnostics company to expand its capabilities in genotyping, enhancing its position in genetic testing and precision medicine.
• Roche Diagnostics announced the introduction of a new genotyping assay aimed at improving cancer treatment by identifying genetic mutations for targeted therapies

List of Leading Companies:

• Thermo Fisher Scientific
• Illumina, Inc.
• Roche Diagnostics
• Agilent Technologies
• Bio-Rad Laboratories, Inc.
• Qiagen N.V.
• PerkinElmer, Inc.
• Abbott Laboratories
• Danaher Corporation
• GE Healthcare
• Pacific Biosciences of California, Inc.
• Thermo Fisher Scientific
• Becton, Dickinson and Company
• Agilent Technologies
• 10x Genomics

Report Scope: